(ABL) Abacus Life - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00258Y1047
ABL: Life Insurance, Policy Services, Investment Products
Abacus Life, Inc. (NASDAQ:ABL) is a specialized financial services firm operating in the alternative asset management and market-making sectors within the United States. The company is structured into three distinct operational segments: Portfolio Servicing, Active Management, and Originations, each targeting different aspects of the life insurance policy market. The Portfolio Servicing segment focuses on providing administrative and policy management services to clients on a contractual basis, ensuring the efficient handling of policy-related tasks. The Active Management segment involves the strategic acquisition, sale, and trading of life insurance policies, with the goal of maximizing returns through active portfolio adjustments and holding policies until their maturity, when death benefits are received. The Originations segment acts as an intermediary, facilitating the sale of life insurance policies between original policyholders and investors, enabling liquidity for policyholders and investment opportunities for buyers.
The company distributes its products and services through a multi-channel approach, including financial advisors, direct-to-consumer platforms, and traditional life settlement intermediaries. This diversified distribution strategy allows Abacus Life to cater to a broad range of customers, from individual investors to institutional buyers. Founded in 2004 and headquartered in Orlando, Florida, Abacus Life has established itself as a key player in the life settlements market, with a focus on creating value for both policy sellers and investors. The companys operations are supported by its expertise in policy valuation, risk management, and regulatory compliance, which are critical in the complex and highly regulated life insurance secondary market.
From a financial perspective, Abacus Life operates with a market capitalization of $715.17 million, reflecting its position as a mid-sized player in the industry. The companys forward P/E ratio of 10.57 suggests investor expectations of future earnings growth, while the P/B ratio of 2.90 indicates that the market values the companys assets at a premium. The P/S ratio of 6.98 highlights the relatively high valuation of its revenue streams. However, the negative return on equity (RoE) of -4.62% raises questions about the companys profitability and its ability to generate returns for shareholders. As the life settlements market continues to evolve, Abacus Lifes ability to navigate regulatory changes, improve operational efficiency, and expand its market share will be critical to its long-term success.
Looking ahead, the future outlook for Abacus Life hinges on its ability to balance growth with profitability. The life settlements market is expected to grow, driven by aging populations and the increasing demand for alternative investment opportunities. However, competition is intensifying, with both established players and new entrants vying for market share. Abacus Lifes success will depend on its ability to differentiate itself through superior policy valuation, efficient operations, and a strong distribution network. From a valuation standpoint, the companys forward P/E ratio suggests that investors are pricing in expectations of future growth, but the negative RoE underscores the need for operational improvements to justify these valuations. If Abacus Life can address its profitability challenges while capitalizing on market growth, it may be well-positioned to deliver value to its shareholders over the long term.
Additional Sources for ABL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ABL Stock Overview
Market Cap in USD | 729m |
Sector | Financial Services |
Industry | Insurance - Life |
GiC Sub-Industry | Insurance Brokers |
IPO / Inception | 2020-09-14 |
ABL Stock Ratings
Growth 5y | -39.1% |
Fundamental | -14.9% |
Dividend | 0.0% |
Rel. Strength Industry | -48.3 |
Analysts | 4.75/5 |
Fair Price Momentum | 6.52 USD |
Fair Price DCF | - |
ABL Dividends
No Dividends PaidABL Growth Ratios
Growth Correlation 3m | -31.9% |
Growth Correlation 12m | -90.4% |
Growth Correlation 5y | -4.4% |
CAGR 5y | -5.38% |
CAGR/Max DD 5y | -0.11 |
Sharpe Ratio 12m | -0.81 |
Alpha | -44.47 |
Beta | 0.40 |
Volatility | 44.05% |
Current Volume | 160.6k |
Average Volume 20d | 162.7k |
As of March 16, 2025, the stock is trading at USD 7.62 with a total of 160,646 shares traded.
Over the past week, the price has changed by +2.56%, over one month by -0.65%, over three months by -3.05% and over the past year by -37.64%.
Neither. Based on ValueRay Fundamental Analyses, Abacus Life is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.91 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABL as of March 2025 is 6.52. This means that ABL is currently overvalued and has a potential downside of -14.44%.
Abacus Life has received a consensus analysts rating of 4.75. Therefor, it is recommend to buy ABL.
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ABL Abacus Life will be worth about 7.1 in March 2026. The stock is currently trading at 7.62. This means that the stock has a potential downside of -7.09%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 13.9 | 82.2% |
Analysts Target Price | 13.9 | 82.2% |
ValueRay Target Price | 7.1 | -7.1% |